Q-omics provides the consensus-scored ZMYM5 profile across patient tissues and cancer cell-line models. ZMYM5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZMYM5 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ZMYM5 RNA expression shows 21,146 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KICH, and ACC as cancer lineages where ZMYM5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZMYM5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZMYM5 survival associations across molecular data types. ZMYM5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZMYM5 RNA expression–survival associations across cancer types. High ZMYM5 expression shows unfavorable associations in CESC, ESCA, COAD, ACC and OV, but favorable associations in KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CESC as the clearest survival context for ZMYM5 RNA expression.
This table summarizes ZMYM5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZMYM5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZMYM5 shows lower tumor expression in KICH and UCEC and higher tumor expression in CHOL, COAD, LIHC and PAAD. The KICH box plot shows higher ZMYM5 RNA expression in normal versus tumor tissue (log2 FC = −1.632, t-test p < 0.001).
This table shows molecular features associated with ZMYM5 in patient tissues and cancer cell lines. In patient samples, ZMYM5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZMYM5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
